Rivaroxaban is a new oral anticoagulant that is a direct factor Xa inhibitor.
1. Mechanism of action
Coagulation factor Xa plays a key role in the coagulation process. It is at the intersection of the endogenous and exogenous coagulation pathways and converts prothrombin into thrombin. Rivaroxaban acts directly on coagulation factor Xa, and by selectively inhibiting its activity, it blocks the production of thrombin, thus effectively inhibiting blood coagulation.
2. Clinical application scenarios
After orthopedic surgery (e.g. hip or knee replacement), patients are at a higher risk of venous thrombosis due to surgical trauma, prolonged bed rest, and other factors. Rivaroxaban can effectively reduce the risk of VTE in these patients, including the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to DVT detachment.
Rivaroxaban can be used to treat patients who have been diagnosed with VTE and can dissolve blood clots that have already formed and reduce symptoms such as swelling and pain in the legs. In patients with non-valvular atrial fibrillation, blood tends to pool in the atria and form blood clots as the atria lose their normal rhythmic contraction. Rivaroxaban can reduce the risk of stroke in these patients and prevent serious consequences such as cerebral embolism caused by dislodged blood clots.
3. Advantages and Features
Easy to use: Rivaroxaban is an oral preparation, which is relatively simple to use compared to traditional anticoagulants (such as warfarin) that require frequent monitoring of coagulation parameters and dosage adjustment. Patients do not need to go to the hospital for frequent blood tests to adjust the dosage, which greatly improves patient compliance.
Rapid onset of action and stable effect: After oral administration, it can be absorbed quickly and exert an anticoagulant effect. Moreover, its anticoagulant effect is relatively stable, and it can maintain anticoagulant status effectively under appropriate dosage, which reduces the risk of insufficient anticoagulation or over-anticoagulation.







